Results for this period
Full year1 March 2025–28 February 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In addition to improving employment and income conditions, growth in inbound foreign visitors, steady sales of related products and growth in the number of prescriptions filled, the company opened 110 new stores, closed 46 stores, acquired 72 dispensing pharmacies, renovated 217 stores, advanced promotional activities and DX in dispensing operations, and optimized staff allocation.
No applicable items. “There are no applicable matters.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2025–28 February 2026 |
| Net Sales | ¥1,010,336 million (YoY +15.1%) |
| Operating profit | ¥48,568 million (YoY +14.1%) |
| Ordinary income | ¥50,062 million (YoY +19.2%) |
| Profit attributable to owners of the parent | ¥44,982 million (YoY +75.1%) |
| Net income per share | ¥248.56 |
| Operating Margin | 4.8% |
| Equity ratio | End of the current fiscal period 47.3 / End of previous period 50.6 |
| Total assets | ¥614,493 million |
| Net assets | ¥290,474 million |
| Cash flows from operating activities | ¥86,779 million |
| Cash flows from investing activities | ¥-69,639 million |
| Cash flows from financing activities | ¥41,213 million |
| Cash and cash equivalents at end of period | ¥111,150 million |
| Full-year earnings forecast | Net Sales ¥1,092,000 million (YoY +8.1%) / Operating profit ¥54,000 million (YoY +11.2%) / Ordinary income ¥55,000 million (YoY +9.9%) / Net income ¥32,800 million (YoY -27.1%) |
| Annual Dividend Forecast | 35 yen (per share, before taking the stock split into account) → 35 yen (per share, before taking the stock split into account)（0.0%） |
| Payout ratio | 14.1% actual for FY2026 February; 19.3% forecast for FY2027 February |
| Shareholder Return Policy | The company intends to provide continuous and stable dividends, taking into comprehensive consideration consolidated results, the total payout ratio and free cash flow, among other factors. Numerical targets: not disclosed. |
| Depreciation and amortization | ¥17,660 million |
| Impairment loss | ¥5,761 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥440 million, Gain on bargain purchase ¥531 million / Extraordinary loss Impairment Losses ¥5,761 million, Impairment loss on investment securities ¥102 million |
| Disclosure regarding the going concern assumption | No applicable items. “There are no applicable matters.” |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name I&H株式会社 |
| Material subsequent events | On 12 March 2026, the company issued its first unsecured straight bonds, with a total issue amount of ¥22,500 million. In addition, 株式会社セキ薬品 is scheduled to become a consolidated subsidiary with a voting-rights ratio of 51.0% effective 1 September 2026. The company also resolved to conduct a 2-for-1 stock split effective 1 September 2026 and amend its Articles of Incorporation. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 189,992,514 |
| Treasury Shares at Period-End | 9,019,684 |
| Factors Behind Changes in Business Performance | In addition to improving employment and income conditions, growth in inbound foreign visitors, steady sales of related products and growth in the number of prescriptions filled, the company opened 110 new stores, closed 46 stores, acquired 72 dispensing pharmacies, renovated 217 stores, advanced promotional activities and DX in dispensing operations, and optimized staff allocation. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company advanced dominant store expansion in the Kanto, Chubu and Kansai regions, accelerated the ramp-up of new stores, renovated existing stores, conducted promotions based on purchasing data, expanded and renovated dispensing rooms and waiting areas, strengthened prescription acquisition, promoted DX in dispensing operations and optimized staff allocation. These initiatives were undertaken against a backdrop of improving employment and income conditions, an increase in inbound foreign visitors, steady sales of health and beauty care products, daily necessities and food, and growth in the number of prescriptions filled.